Cargando…
Variability within rare cell states enables multiple paths towards drug resistance
Molecular differences between individual cells can lead to dramatic differences in cell fate, such as death versus survival of cancer cells upon drug treatment. These originating differences remain largely hidden due to difficulties in determining precisely what variable molecular features lead to w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277666/ https://www.ncbi.nlm.nih.gov/pubmed/33619394 http://dx.doi.org/10.1038/s41587-021-00837-3 |
_version_ | 1783722121377087488 |
---|---|
author | Emert, Benjamin L. Cote, Christopher Torre, Eduardo A. Dardani, Ian P. Jiang, Connie L. Jain, Naveen Shaffer, Sydney M. Raj, Arjun |
author_facet | Emert, Benjamin L. Cote, Christopher Torre, Eduardo A. Dardani, Ian P. Jiang, Connie L. Jain, Naveen Shaffer, Sydney M. Raj, Arjun |
author_sort | Emert, Benjamin L. |
collection | PubMed |
description | Molecular differences between individual cells can lead to dramatic differences in cell fate, such as death versus survival of cancer cells upon drug treatment. These originating differences remain largely hidden due to difficulties in determining precisely what variable molecular features lead to which cellular fates. Thus, we developed Rewind, a methodology that combines genetic barcoding with RNA FISH to directly capture rare cells that give rise to cellular behaviors of interest. Applied to BRAF(V600E) melanoma, we trace drug-resistant cell fates back to single-cell gene expression differences in their drug-naive precursors (initial frequency of ~1:1000–1:10,000 cells) and relative persistence of MAP-kinase signaling soon after drug treatment. Within this rare subpopulation, we uncover a rich substructure in which molecular differences between several distinct subpopulations predict future differences in phenotypic behavior, such as proliferative capacity of distinct resistant clones following drug treatment. Our results reveal hidden, rare-cell variability that underlies a range of latent phenotypic outcomes upon drug exposure. |
format | Online Article Text |
id | pubmed-8277666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-82776662021-08-22 Variability within rare cell states enables multiple paths towards drug resistance Emert, Benjamin L. Cote, Christopher Torre, Eduardo A. Dardani, Ian P. Jiang, Connie L. Jain, Naveen Shaffer, Sydney M. Raj, Arjun Nat Biotechnol Article Molecular differences between individual cells can lead to dramatic differences in cell fate, such as death versus survival of cancer cells upon drug treatment. These originating differences remain largely hidden due to difficulties in determining precisely what variable molecular features lead to which cellular fates. Thus, we developed Rewind, a methodology that combines genetic barcoding with RNA FISH to directly capture rare cells that give rise to cellular behaviors of interest. Applied to BRAF(V600E) melanoma, we trace drug-resistant cell fates back to single-cell gene expression differences in their drug-naive precursors (initial frequency of ~1:1000–1:10,000 cells) and relative persistence of MAP-kinase signaling soon after drug treatment. Within this rare subpopulation, we uncover a rich substructure in which molecular differences between several distinct subpopulations predict future differences in phenotypic behavior, such as proliferative capacity of distinct resistant clones following drug treatment. Our results reveal hidden, rare-cell variability that underlies a range of latent phenotypic outcomes upon drug exposure. 2021-02-22 2021-07 /pmc/articles/PMC8277666/ /pubmed/33619394 http://dx.doi.org/10.1038/s41587-021-00837-3 Text en http://www.nature.com/authors/editorial_policies/license.html#termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Emert, Benjamin L. Cote, Christopher Torre, Eduardo A. Dardani, Ian P. Jiang, Connie L. Jain, Naveen Shaffer, Sydney M. Raj, Arjun Variability within rare cell states enables multiple paths towards drug resistance |
title | Variability within rare cell states enables multiple paths towards drug resistance |
title_full | Variability within rare cell states enables multiple paths towards drug resistance |
title_fullStr | Variability within rare cell states enables multiple paths towards drug resistance |
title_full_unstemmed | Variability within rare cell states enables multiple paths towards drug resistance |
title_short | Variability within rare cell states enables multiple paths towards drug resistance |
title_sort | variability within rare cell states enables multiple paths towards drug resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277666/ https://www.ncbi.nlm.nih.gov/pubmed/33619394 http://dx.doi.org/10.1038/s41587-021-00837-3 |
work_keys_str_mv | AT emertbenjaminl variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT cotechristopher variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT torreeduardoa variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT dardaniianp variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT jiangconniel variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT jainnaveen variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT shaffersydneym variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance AT rajarjun variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance |